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Abstract  Sleep  disturbance  has  been  described  in  cystic  ﬁbrosis  (CF)  patients  as  relevant
to clinical  and  lung  function  predictive  factors  helping  to  improve  the  diagnosis  and  early
intervention.  Related  paediatric  studies  are  scarce.
Objective:  To  describe  respiratory  sleep  disturbance  (RSD)  and  its  association  with  spirometric
indices  in  a  population  of  CF  children.  A  second  aim  was  to  determine  if  spirometric  indices
and wake-time  SpO2 are  predictors  of  sleep  disturbance.
Methods:  A  cross-sectional  study  involving  33CF  paediatric  patients.  All  participants  underwent
in-lab polysomnography  (PSG),  pulse  oximetry  and  spirometry.  A  standardized  sleep  question-
naire was  completed  for  each  patient.  Two  subgroups  were  considered:  I  --  Normal  (FEV1 >  −1.64
z-score); II  --  Obstructed  (FEV1 ≤  −1.64  z-score).
Results:  Participant’s  median  age  was  12  (6--18)  years,  16  (48.5%)  were  male.  Twenty-nine
patients  (87.9%)  presented  sleep  complaints.  Sleep  efﬁciency  was  reduced;  sleep  latency  and
waking after  sleep  onset  (WASO)  increased.  N1  increased,  N2,  N3,  REM  and  awakenings  were
normal. The  apnoea--hypopnoea  index  was  0.6/h  (sd  0.9);  respiratory  disturbance  index  (RDI)
was 6.6/h  (sd  5.2).  Mean  awaking  (97%  (sd  1.1))  and  sleep  SpO2 (95%  (sd  2.7))  were  normal;
Abbreviations: AHI, apnoea/hypopnoea index; BMI, body mass index; CF, cystic ﬁbrosis; CFTR, cystic ﬁbrosis transmembrane condutance
egulator; ERS, European Respiratory Society; FEF25--75, forced expiratory ﬂow between 25% and 75% of maximal expiratory ﬂow; FEV1, forced
xpiratory volume in 1 s; FL, ﬂow limitation; FVC, forced vital capacity; HSM, Hospital de Santa Maria; N1, sleep stage 1; N1%TST, time in
1 as a percentage of total sleep time; N2, sleep stage 2; N2%TST, time in N2 as a percentage of total sleep time; N3, sleep stage 3; N3%
ST, time in N3 as a percentage of total sleep time; NREM, non REM sleep; ODI, oxygen desaturation index; PSG, polysomnography; RDI,
espiratory disturbance index; REM, rapid eye movement; REM%, time in REM as a percentage of total sleep time; REML, REM latency; RSD,
espiratory sleep disturbance; SE, sleep efﬁciency; SL, sleep latency; SQ, sleep questionnaire; SpO2, pulse oximetry; SpO2mean, mean pulse
ximetry value; SpO2min, minimal pulse oximetry value; tcCO2, transcutaneous CO2; TST, total sleep time; W, wake; WASO, wake after
leep onset.
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mean  nocturnal  oximetry  desaturation  index  was  2.36/h;  minimal  nocturnal  SpO2 was  89%
(sd 4.1).
We  found  associations  between  mean  nocturnal  SPO2 and  mean  values  of  FEV1 (r  =  0.528;
p =  0.002)  and  FEF25--75 (r  =  0.426;  p  =  0.013).  There  were  signiﬁcant  differences  in  nocturnal  SpO2
between  normal  and  obstructed  patients  (p  <  0.000).  PSG  data  correlated  with  the  questionnaire
answers for  night  awakenings  and  WASO  (p  =  0.985)  and  difﬁcult  breathing  during  sleep  and  RDI
(p =  0.722).
This  study  points  to  most  CF  children  having  sleep  complaints,  and  highlights  the  correlation
between subjective  assessment  of  sleep  and  PSG  and  spirometric  results.  Awake-time  SpO2 and
spirometric  values  are  possible  risk  predictors  for  nocturnal  desaturation.
© 2016  Sociedade  Portuguesa  de  Pneumologia.  Published  by  Elsevier  Espan˜a,  S.L.U.  This  is  an
open access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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sIntroduction
Sleep  disturbance  in  cystic  ﬁbrosis  (CF)  patients  has
been  increasingly  recognized  in  all  ages.1--6 Respiratory
sleep  disturbance  (RSD),  with  nocturnal  desaturation4,7 and
hypoventilation6 has  been  described  in  association  with
chronic  lung  disease  and  respiratory  failure1,8 as  well  as  with
cough9,10 and  upper  airway  obstruction.11,12 Sleep  fragmen-
tation  and  poor  sleep  quality  are  also  reported.6,11,13
It  is  not  clear  in  what  way  RSD  modulates  the  clinical
course  of  children  with  CF,14 but  it  interferes  with  quality  of
life.11 Other  factors  contributing  to  poor  sleep  quality  in  CF
patients  are  night  anguish,  fear  of  death,  drug  effects  and
the  need  for  nocturnal  therapies.11,14,15
Lung  function  measures,  in  particular  spirometric
indices,  are  critical  for  the  assessment  and  management  of
CF  patients;  they  are  a  primary  diagnostic,  therapeutic  and
prognostic  endpoint.16--20 Few  reports  have  evaluated  lung
function  tests  and  awake  pulse  oxymetry  (SpO2)  as  predic-
tors  of  sleep  disturbance  in  children  with  CF  and  the  results
are  contradictory.6,14,15,21
Our  main  objective  was  to  describe  respiratory  sleep  dis-
turbance  in  a  population  of  clinically  stable  children  and
adolescents  with  CF.  Our  aim  was  also  to  identify  if  spiro-
metric  indices  (FEV1,  FEF25--75,  FEV1/FVC)  and  awake-time
SpO2 could  be  predictors  of  sleep  disturbance.
Methods
This  was  an  observational,  prospective,  cross-sectional  and
descriptive--analytical  study.  Children  were  recruited  from
the  Paediatric  Unit  of  a  Specialized  Centre  for  Cystic  Fibrosis
of  a  Tertiary  Care  Hospital,  between  February  and  October
2013.  Written  informed  consent  was  obtained  from  parents
of  children  under  16  years-old  and  from  patients  above  that
age.
All  but  one  patient  had  CF  conﬁrmed  by  the  pres-
ence  of  two  transmembrane  regulator  (CFTR)  mutations;
one  child  had  one  CFTR  mutation  with  a  sweat  chloride
test  >60  mmol/l,  associated  with  characteristic  phenotype;
twenty-one  (63.6%)  were  homozygote  for  the  mutation
DelF508.
b
l
s
tClinical  stability,  deﬁned  as  the  absence  of  respira-
ory  exacerbations  and  increased  tiredness,  maintenance
f  weight  gain  and  stable  FEV1, for  a  month  previous  to
he  study  was  required  for  inclusion.  Exclusion  criteria  were
hronic  respiratory  failure  or  being  unable  to  cooperate  dur-
ng  spirometry.
Body  mass  index  (BMI)  was  assessed  and  reported  as  z-
core.
All  participants  or  their  parents  completed  a  stan-
ardized  sleep  questionnaire  (SQ)  before  polysomnography
PSG);  daytime  SpO2 and  spirometry  were  performed  the
ollowing  day.
SQ  is  a non  validated  but  routinely  applied  questionnaire
t  the  Paediatric  Sleep  Laboratory.  SQ  has  been  developed
s  a  rapid  screening  tool  based  on  the  Paediatric  Sleep
uestionnaire22 and  the  Sleep  Apnea  Questionnaire.23 It
ncludes  questions  about  sleep  quality,  night-time  and  day-
ime  symptoms  and  signs  of  RSD  and  sleep  disturbance,  and
ssociated  events  like  parasomnias.
In-lab  PSG  (SomnoScreen® Plus  TM  Domino  Software,
.2.3.1)  was  performed  for  a  minimum  of  7  h.  The  fol-
owing  parameters  were  recorded  at  the  same  time:  six
hannel  electroencephalogram,  bilateral  electrooculogram,
nterior  tibialis  and  chin  electromyogram,  electrocardio-
ram,  oronasal  thermistor  airﬂow  detection,  nasal  cannula
ransducer,  body  position,  tracheal  microphone,  thoracic
nd  abdominal  movements  using  respiratory  effort  bands
nd  pulse  oximetry.
A  desaturation  event  was  deﬁned  as  a  decrease  of
pO2 ≥  3%.  Mean  and  minimum  SpO2 were  determined  as
ell  as  the  percentage  of  total  sleep  time  with  SpO2 <  90%.
nalysis  of  sleep  stages,  arousals,  movements  and  respi-
atory  events  was  performed  according  to  the  American
cademy  of  Sleep  Medicine  manual.24--26 Flow  limitation  was
eﬁned  as  a ﬂattening  of  the  inspiratory  portion  of  the  ﬂow
aveform  detected  by  nasal  cannula  pressure  during  sleep
ithout  criteria  of  hipopnoea.  The  sleep  data  included  were:
ime  in  bed,  deﬁned  as  time  from  lights  out  to  lights  on;
leep  efﬁciency  (SE),  calculated  as  total  sleep  time  divided
y  the  total  time  in  bed;  sleep  latency  (SL),  deﬁned  from
ights  out  until  the  ﬁrst  epoch  of  any  sleep  stage;  wake  after
leep  onset  (WASO),  deﬁned  as  time  spent  awake  between
he  sleep  onset  and  the  end  of  sleep;  REM  latency  (REML)
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eﬁned  as  time  between  sleep  onset  to  the  ﬁrst  REM  epoch.
leep  stages  duration  is  presented  as  a  percentage  of  total
leep  time  (TST).
Normative  values  according  to  Beck  et  al.,27 were
dopted;  respiratory  disturbance  index  (RDI)  was  deﬁned  as
he  sum  of  all  respiratory  events  (ﬂow  limitations,  apnoeas,
ipopnoeas)  and  was  interpreted  according  to  Uliel.28
Continuous  transcutaneous  CO2 (SENTEC® digital  V-ST-
T2.02)  monitoring  was  performed  to  assess  median  and
aximal  tcCO2.
Awake  SpO2 was  assessed  by  digital  measure  with  Nonin®
500  (Nonin  Medical  Inc.,  Plymouth,  MN,  USA),  the  mean
f  at-rest  values  obtained  over  one-minute  period  of  the
lestismographic  wave  form  stability,  with  the  patient  in  a
itting  position.
Spirometry  (Jaeger  Master  Screen  PFT® --  Viasys  Health-
are,  v.5.3.0)  was  performed  according  to  the  American
horacic  Society  and  the  European  Respiratory  Society
riteria29 for  patients  ≥6  years  of  age;  values  were
xpressed  in  z-scores  according  to  the  equations  from  the
rowing  lung  initiative  (growinglungs.org.uk).30 The  sample
as  then  stratiﬁed  according  to  FEV1 as  Group  I,  within
ormal  clinical  range  values  (z-score  >  −1.64)  and  Group  II,
lassiﬁed  as  obstructive  (z-score  ≤  −1.64).
Descriptive  statistics,  correlations  by  Pearson’s  coef-
cient,  Mann--Whitney  test  and  K--Smirnov  test  were
erformed  as  appropriate  and  a  signiﬁcance  level  of  5%  was
onsidered.  Statistical  Package  for  the  Social  Sciences  21.0
SPSS,  Chicago,  IL,  USA)  was  used  for  all  tests.
esults
orty-ﬁve  CF  patients  aged  between  6  and  18  years  old
ere  recruited  and  33  were  included.  Eight  patients  refused
o  participate  in  the  study  and  four  were  excluded:  two
ad  home  ventilation  or  oxygen  therapy,  one  an  uncon-
rmed  diagnosis  and  another  was  not  clinically  stable  during
he  study  period.  Sixteen  (48.5%)  patients  were  male;  the
edian  age  was  12  (6--18)  years-old.  Median  age  at  CF
i
w
a
t
Table  1  Demographics  and  spirometry  results.
Total  popul
N  =  33
Characteristics  of  the  patients
Age  (years)  12.27  ±  3  
Diagnostic age  (months)  (median(min-max))  11  (0-118)  
Males (n)  (%)  16  (48.5)  
BMI z-score  −0.35  ±  0.7
Spirometry
FVC z-score  (mean)  −1.09  ±  1.4
FEV1 z-score  (mean)  −1.76  ±  1.6
FEV1/FVC  z-score  (mean)  −1.31  ±  1.0
FEF25--75 z-score  (mean)  −2.06  ±  1.6
FVC -- forced vital capacity; FEV1 -- forced expiratory volume in 1 s; FE
expiratory ﬂow.
a Mann--Whitney test.A.M.  Silva  et  al.
iagnosis  was  11  (0--118)  months.  Average  BMI  z-score  was
ormal  (−0.35  ±  0.78)  (Table  1).
uestionnaire  results
wenty-nine  patients  (87.9%)  reported  poor  sleep  quality
nd/or  RSD:  19  (57.6%)  complained  of  impaired  sleep  onset
nd  awaking  more  than  twice  per  night;  15  (45.5%)  reported
ifﬁcult  breathing  during  sleep  and  19  (57.6%)  reported  snor-
ng,  29  (87.9%)  stated  they  stopped  breathing  during  sleep
nd  21  (63.7%)  were  mouth  breathers.  Daytime  symptoms
ere  rare,  and  the  most  common  was  inattentive  behaviour
39.4%).  More  than  half  of  the  patients  mentioned  sleep
alking  (54.5%).  Parasomnias  were  not  relevant.
olysomnography  results
leep  structure
ean  TST  was  6.7  ±  0.59  h,  with  decreased  SE  (79.91  ±
0.98%)  and  increased  SL  (37  ±  33.07  min)  and  WASO
65.65  ±  39.54  min).  REML  was  normal  (143.39  ±  80.09  min),
nd  so  was  stages  distribution  N2  (43.8  ±  8.9%TST),  N3
26.4  ±  7.8%TST)  and  REM  (19.32  ±  6.3%TST);  N1  was  slightly
levated  (5.88  ±  5.4%TST)  and  showed  a  negative  associa-
ion  with  sleep  efﬁciency  (r  =  −0.561;  p  =  0.001).  The  arousal
ndex  (5  ±  2.39/h)  was  within  normal  range  (Table  2).
espiratory  events
ean  apnoea/hypopnoea  index  (AHI)  was  0.6  ±  0.9/h
f  sleep;  mean  ﬂow  limitations  (44.9  ±  38.7)  and  RDI
6.6  ±  5.2/h)  were  slightly  increased  (Table  2).  Twenty-nine
87.9%)  patients  presented  paradoxical  breathing  and  eight
24.2%)  snored.
octurnal  gas  exchange
ean  awake  (97  ±  1.1%)  and  nocturnal  SpO2 (95  ±  2.7%)  weren  the  normal  range.  Mean  oxygen  desaturation  index  (ODI)
as  2.36  ±  2.40/h;  minSpO2 was  89%  ±  4.1%  (Table  2).  Aver-
ge  median  values  of  tcCO2 was  normal  (40.18  ±  4.8  mmHg).
cCO2 mean  maximal  value  was  45.39  (±5.16)  mmHg.
ation Group  I
N  =  13
Group  II
N  =  20
pa
11.62  ±  3.65  13  ±  3.07  0.576
6  (1-118)  14.5  (0-108)  0.654
6  (46.1)  10  (50)  --
8  0.11  ±  0.79  −0.59  ±  0.68  0.327
6  0.25  ±  0.97  −1.96  ±  0.96  0.065
0  −0.12  ±  0.95  −2.83  ±  0.81  0.001
4  −0.68  ±  0.62  −1.73  ±  1.05  0.080
2  −0.80  ±  1.22  −2.89  ±  1.25  0.002
F25--75 -- forced expiratory ﬂow between 25% and 75% of maximal
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Table  2  Polysomnography  analysis.
Sleep  structure  Respiratory  events
TST  (h) 6.70  ±  0.59 AHI  (n/h)  0.60  ±  0.90
SE (%)  79.91  ±  10.98  FL  (n)  44.90  ±  38.70
SL (min)  37.95  ±  33.01  RDI  (n/h)  6.60  ±  5.20
W (min)  103.61  ±  53.84  Sleep  SpO2 mean  (%)  95.00  ±  2.70
WASO (min)  65.65  ±  39.54  Sleep  SpO2 min  (%)  89.00  ±  4.10
REML (min)  143.39  ±  80.09  SpO2 <  90  (%TST)  1.75  ±  6.80
N1 (%TST)  5.88  ±  5.40  ODI  (n/h)  2.36  ±  2.40
N2 (%TST)  48.38  ±  8.18  Awake  SpO2 (%)  97.00  ±  1.10
N3 (%TST) 26.40  ±  7.84 tcCO2 median  (mmHg) 40.18  ±  4.80
REM (%TST) 19.32  ±  6.34 tcCO2 max  (mmHg) 45.39  ±  5.16
Sleep arousals  (n/h) 5.00  ±  2.39
TST -- total sleep time; SE -- sleep efﬁciency; SL -- sleep latency; W -- wake; WASO -- wake after sleep onset; REML -- REM latency; N1
(%TST) -- time in N1 (%); N2 (%TST) -- time in N2 (%); N3 (%TST) -- time in N3 (%); REM (%TST) -- time REM (%); AHI -- apnoea/hypopnoea
DI -- oxygen dessaturation index; Sleep SpO2 mean -- mean sleep pulse
-- transcutaneous CO2 (median and maximal).
3.00
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aindex; FL -- ﬂow limitation; RDI -- respiratory disturbance index; O
oximetry; Sleep SpO2 min -- minimal sleep pulse oximetry; tcCO2
Awake  and  sleep  SpO2 were  positively  correlated
(r  =  0.426;  p  =  0.064)  and  although  without  statistical  signiﬁ-
cance  this  may  be  clinically  relevant.  The  mean  ODI  showed
moderate  negative  correlation  with  minimal  nocturnal
SpO2 (r  =  −0.532;  p  =  0.001)  and  with  mean  nocturnal  SpO2
(r  =  −0.358;  p  = 0.041).  A  negative  moderate  correlation  was
found  between  awake  SpO2 and  AHI  (r  =  −0.469;  p  =  0.006).
Spirometric  indices  analysis
Mean  global  z-score  was  reduced  for  FEV1 (−1.76  ±  1.60)
and  for  FEF25--75 (−2.06  ±  1.62).  Thirteen  patients  had  FEV1
within  the  normal  range  (Group  I)  and  20  patients  had
FEV1 ≤  −1.64  z-score  and  were  classiﬁed  as  obstructed
(Group  II).  Mean  z-score  for  FVC  and  for  FEV1/FVC  was  nor-
mal  (Table  1).
Polysomnographyc  and  spirometric  results  association
analysis
As  deﬁned  by  FEV1,  compared  to  Group  I,  patients  from
Group  II  showed  a  trend  towards  a  lower  mean  SE
(81.03  ±  12.05%  vs  79.17  ±  10.98%;  p  =  0.478),  more  sleep
arousals  (4.69  ±  1.63/h  vs  5.12  ±  2.69/h;  p  =  0.235)  and
increased  WASO  (52.58  ±  35.06  min  vs  74.12  ±  40.79  min;
p  =  0.169),  although  none  reached  statistical  signiﬁcance
(Table  3).
No differences  between  groups  were  found  for  respira-
tory  events  during  sleep.  A  signiﬁcant  difference  was  found
for  mean  sleep  SpO2,  lower  in  Group  II  (94.10  ±  3.21%  vs
96.53  ±  0.77%;  p  <  0.000);  minimal  sleep  SpO2 (88.75  ±  4.77%
vs  90.38  ±  3.01)  was  also  without  statistical  signiﬁcance
(p  =  0.456).  Mean  median  tcCO2 was  normal  in  both  groups
(Table  3).  Analysis  for  FEF25--75 presented  similar  results.
FEV1 was  positively  associated  with  average  sleep  SpO2
(r  =  0.528;  p =  0.002)  (Fig.  1)  and  minimal  sleep  SpO2
(r  =  0.405;  p  =  0.019).  A  moderate,  negative  association
between  awake  SpO2 and  AHI  (r  =  −0.469;  p  =  0.006)  was
found.
Maximal  tcCO2 was  negatively  and  moderately  associated
with  average  sleep  SpO2 (r  =  −0.387;  p  =  0.026).
o
o
w
t2
Figure  1  Association  of  FEV1 and  sleep  SpO2.
olysomnography  data  and  sleep  questionnaire
ssociation  analysis
SG  data  signiﬁcantly  correlated  with  the  questionnaire
nswers  for  night  awakenings  and  WASO  (p  =  0.985),  and  for
ifﬁcult  breathing  during  sleep  and  RDI  (p  =  0.722).  Difﬁculty
n  falling  asleep  correlated  moderately  with  SL  (p  =  0.345).
o  association  was  found  for  snoring  reported  in  the  SQ  and
n  the  PSG  (p  =  0.039)  or  for  breathing  interruption  during
leep  (p  =  0.039)  and  AHI  (p  =  0.049).
iscussion
o  the  best  of  our  knowledge  this  is  the  ﬁrst  study  in  a  CF
ortuguese  Paediatric  population  to  evaluate  sleep  disturb-
nce  and  to  try  to  relate  it  to  spirometric  indices,  a clinical
iagnostic  and  prognostic  relevant  endpoint.16
There  are  some  studies  involving  adult  CF  patients  and
F  children  but  only  during  acute  illness  or  with  higher  clin-
cal  severity.1,7,13,31 Most  studies  presented  limitations  such
s  small  population  samples,  sleep  assessment  performed
nly  through  sleep  questionnaires  and/or  evaluated  by  pulse
ximetry  analysis.6,15,32 Only  a  few  studies  assessed  sleep
ith  PSG  or  quantiﬁed  severity  of  lung  disease  with  an  objec-
ive  measure  like  spirometry,  as  we  did.1,7,11,13,33
206  A.M.  Silva  et  al.
Table  3  Polysomnography  events  according  to  FEV1 z-score  group  analysis.
FEV1  z-score
Group  I
N  =  13
Group  II
N =  20
pa
TST  (h)  6.81  ±  0.81  6.70  ±  1.11  0.758
SE (%)  81.03  ±  12.05  79.17  ±  10.48  0.478
SL (min)  49.88  ±  45.97  30.20  ±  18.45  0.478
W (min)  102.46  ±  64.97  104.35  ±  47.07  0.501
WASO (min) 52.58  ±  35.06 74.15  ±  40.79 0.169
REML (min) 136.31  ±  77.54 148.00  ±  83.36 0.813
N1 (%TST) 6.19  ±  5.89 5.68  ±  5.21 0.899
N2 (%TST)  46.29  ±  8.86  49.74  ±  7.62  0.181
N3 (%TST)  27.56  ±  7.97  25.65  ±  7.87  0.524
REM (%TST)  19.90  ±  6.56  18.94  ±  6.33  0.548
Sleep arousals  (n/h) 4.68  ±  1.63 5.12  ±  2.69  0.235
AHI (/h)  0.44  ±  0.48  0.72  ±  1.09  0.785
FL (n)  58.08  ±  48.15  36.45  ±  29.55  0.221
RDI (n/h)  8.69  ±  7.23  5.30  ±  2.77  0.298
Sleep SpO2 mean  (%)  96.53  ±  0.77  94.10  ±  3.21  0.000
Sleep SpO2 min  (%)  90.38  ±  3.01  88.75  ±  4.70  0.456
ODI (n/h)  2.65  ±  2.15  2.17  ±  2.58  0.250
Awake SpO2 (%)  97.23  ±  1.01  96.90  ±  1.20  0.758
tcCO2 median  (mmHg)  40.76  ±  3.85  39.80  ±  5.27  0.598
tcCO2 max  (mmHg)  45.66  ±  5.38  45.26  ±  5.02  0.524
a Mann--Whitney test.
TST -- total sleep time; SE -- sleep efﬁciency; SL -- sleep latency; W -- wake; WASO -- wake after sleep onset; REML -- REM latency; N1
(%TST) -- time in N1 (%); N2 (%TST) -- time in N2 (%); N3 (%TST) -- time in N3 (%); REM (%TST) -- time REM (%); AHI -- apnoea/hypopnoea
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In  this  study,  87.9%  of  clinically  stable  children  between
ix  and  eighteen  years,  with  normal  or  mildly  affected  lung
unction,  were  identiﬁed  as  having  sleep  disturbance,  either
espiratory  or  of  the  sleep  structure.  These  alterations  cor-
espond  to  subjectively  diminished  quality  of  sleep,  even
ith  slight  anomalies  of  PSG  values.  These  ﬁndings  are  con-
istent  with  the  majority  of  other  reports  showing  that  CF
atients  have  lower  sleep  efﬁciency  and  quality.6,11,13,15,34
Difﬁculty  in  breathing  during  sleep  was  reported  in
lmost  half  of  our  patients  and  had  a  positive  association
ith  RDI.  Night  awakenings  and  WASO  (p  =  0.985)  were  also
ssociated.  These  results  conﬁrm  what  was  suggested  by
ilross,33 that  even  a  simple  questionnaire  like  the  one  used
n  this  study  has  an  important  role  in  sleep  disturbance
creening  in  CF  patients.
The  in-lab  ﬁrst  night  effect  must  be  considered  when
valuating  SE  and  SL  disturbance:  sleep  in  the  laboratory  can
nﬂuence  sleep  onset  and  duration,  as  showed  by  Verhulst
t  al.35 who  described  the  ﬁrst  night  effect  in  children  with
SD.  This  study  included  predominantly  adolescents,  and
leep  phase  delay  associated  with  this  age  group  may  act  as
 confounder  to  the  sleep  onset  and  duration  compromise.36
s  in  our  study,  Perin  and  Milross  also  found  higher  wakeful-
ess  and  sleep  latency  leading  to  lower  sleep  efﬁciency  in
13,34F  patients.
In  the  present  study,  arousal  index  was  normal  but  higher
n  the  group  with  higher  respiratory  compromise  evaluated
y  spirometic  indices,  as  described  by  Naqvi  and  Dancey11,31.
d
a
f
coxygen dessaturation index; sleep SpO2 mean -- mean sleep pulse
nscutaneous CO2 (median and maximal).
1  was  elevated  and  showed  a  negative  association  with
leep  efﬁciency,  pointing  to  sleep  fragmentation.  The  higher
ASO  was  more  evident  in  the  group  with  abnormal  FEV1,
ut  no  signiﬁcant  correlation  was  found.
Naqvi  et  al.11 described  an  association  between  the  mag-
itude  of  sleep  structure  disruption  and  the  severity  of  lung
isease,  but  not  with  hypoxaemia  or  hypoventilation  during
leep,  which  is  similar  to  our  results.  We  could  not  stratify
atients  by  severity  levels  because  of  the  small  size  of  the
ample,  but  sleep  structure  compromise  showed  a  tendency
o  be  more  common  in  the  group  with  lower  FEV1.
Ramos  et  al.  studied  a  stable  paediatric  CF  population
nd  described  important  complaints  about  sleep  quality
nd  signiﬁcant  architecture  disruption  as  well  as  preva-
ent  respiratory  sleep  disturbance  and  episodes  of  nocturnal
esaturation.14,15 No  signiﬁcant  respiratory  events  were
egistered  in  our  study.  The  absence  of  major  respiratory  dis-
urbance  can  be  explained  by  the  young  age  of  the  patients,
he  clinical  stability  and  lung  function  preservation  in  this
ample.  Perin  did  not  ﬁnd  higher  prevalence  of  respiratory
leep  disturbance  either,  in  an  adult  CF  population  with  sim-
lar  characteristics.34 We  found  a  lower  SpO2 during  sleep,
s  expected,  and  although  not  in  the  pathological  range,
here  were  some  sleep  desaturations,  which  are  in  accor-
ance  with  other  studies:  Ramos  et  al.,  in  a  group  of  school
ge  CF  children  and  adolescents  identiﬁed  an  intermittent
all  of  nocturnal  SpO2 and  normal  or  minor  lung  function
ompromise.14 Naqvi  has  also  found  reduced  minimal  SpO2,
rosis
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without  signiﬁcant  respiratory  events.  This  data  is  consis-
tent  with  our  ﬁndings,  as  we  identiﬁed  diminished  minimal
SpO2 associated  with  ODI,  but  without  signiﬁcant  respira-
tory  events.  This  author  states  that  apnoea  or  hypopnoea  is
uncommon  in  CF,  even  in  the  presence  of  moderate  to  severe
lung  disease.11
Like  Milross,13 we  found  an  association  between  awake
and  sleep  SpO2,  that  even  without  statistical  signiﬁcance,
can  point  towards  wake  oximetry  as  a  possible  predictive
tool  for  nocturnal  hypoxaemia.  However,  our  sample  is  small
and  inter-patients  variability  of  nocturnal  SpO2 was  high,
which  precludes  us  from  clearly  stating  this.
Another  interesting  ﬁnding  was  the  association  of  awake
SpO2 with  AHI,  which  favours  the  importance  of  wake  oxime-
try  to  anticipate  the  occurrence  of  nocturnal  respiratory
events.  These  ﬁndings  must  be  conﬁrmed  in  larger  samples
and  more  heterogeneous  populations.
The  mild  alterations  of  lung  function  can  be  explained  by
the  clinical  stability  of  this  paediatric  patient  sample,  due  to
progress  made  in  CF  patient  care  that  postpones  more  severe
disease  stages  for  adult  age.34 Our  analysis  was  done  with
spirometric  indices  (FEV1,  FEF25--75 and  FEV1/FVC)  above  or
under  the  cut-off  for  normal  stated  clinical  z-scores  and  we
did  not  include  in  this  study  the  analysis  of  other  clinical  or
radiological  severity  scores,  which  may  limit  the  extrapola-
tion  of  results.  However,  spirometry  by  itself  is  accepted  as
a  marker  of  disease  severity,18--20,28,37 conferring  reliability
to  our  ﬁndings.
We  identiﬁed  signiﬁcant  lower  sleep  SpO2 in  patients  with
FEV1 z-score  under  normal  range,  which  indicates  spiromet-
ric  indices  as  possible  predictors  of  nocturnal  desaturation,
as  described  in  other  studies.4,7,15,38,39
As  in  other  studies,  we  did  not  ﬁnd  any  association
between  sleep  architecture  parameters  and  spirometry.4,7,39
This  study  has  a  few  limitations:  the  in-lab  night  study
may  not  reﬂect  the  usual  sleep  behaviour;  patient  sta-
bility  may  underestimate  the  relationship  between  sleep
disturbance  and  disease  severity;  the  small  sample  dimen-
sion  precluded  us  from  doing  severity  stratiﬁcation,  which
could  have  been  more  accurate  in  identifying  sleep  and  wake
respiratory  compromise;  we  did  not  used  a  quality  of  life
questionnaire,  which  could  have  provided  important  data
on  sleep  disturbance  consequences.
Nevertheless  this  study  forms  the  basis  for  a  relevant  dis-
cussion  about  sleep  compromise  in  a  paediatric  ‘‘healthy’’
group  of  CF  patients.  As  sleep  quality  is  related  to  quality  of
life  and  maintenance  of  good  clinical  condition,  the  results
of  this  study  indicate  that  sleep  evaluation  must  be  con-
sidered  in  the  routine  assessment  of  CF  patients  from  early
stages  of  disease.
Conclusion
This  study  showed  that  most  CF  children  have  complaints
about  sleep  quality,  identiﬁed  by  a  SQ  and  conﬁrmed  by
PSG.
No  clear  association  between  sleep  structure  disruption
and  the  severity  of  lung  disease  was  found,  but  although  not
remarkable,  nocturnal  O2 desaturation  occurred  in  a  clini-
cally  stable  sample  of  CF  paediatric  patients  associated  with
respiratory  disease  severity  assessed  by  spirometry.
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Further  studies  are  needed  in  more  representative  popu-
ations  with  a  higher  clinical  severity  span  to  conﬁrm  our
esults.
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